XENCOR LICENSES CHRONOS' ACE TO GENERATE PDA CELL LINES.Chromos You may be looking for:
TSX Transfer from Stack Pointer to Index
TSX True Space Extension : CHR CHR
canine hypoxic rhabdomyolysis. ) and Xencor have entered into a non-exclusive research license agreement to develop cell lines that express Xencor's monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and other recombinant protein recombinant protein Molecular biology A protein encoded by recombinant DNA or generated from a recombinant gene. See Recombinant pharmacology. product candidates.
Under the terms of the agreement, Xencor will use the ACE System platform to generate cell lines expressing proteins derived from its Protein Design Automation (PDA (Personal Digital Assistant) A handheld computer for managing contacts, appointments and tasks. It typically includes a name and address database, calendar, to-do list and note taker, which are the functions in a personal information manager (see PIM). ) technology. Xencor also receives an option to negotiate a commercial license for manufacturing its clinical products. PDA(R) technology is used to identify and optimize novel protein lead candidates. Chromos will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed.
"This relationship is significant to Chromos as it further demonstrates the versatility of our ACE System in the product development pathway," said Chromos president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Alistair Duncan. "Our ability to rapidly and efficiently generate high expressing cell lines provides our partners with a potentially seamless process for protein production from pre-clinical research through to commercial manufacturing. This deal is another step towards positioning the ACE System as the industry's platform of choice for protein production."
"Xencor's capabilities will be significantly broadened by access to Chromos' ACE System for enabling expression of our therapeutic candidates," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "The combination of our PDA(R) technology linked to Chromos' protein expression platform will enhance our ability to rapidly identify and advance protein candidates through the product development pathway."
Xencor discovers and develops protein therapeutics using its proprietary rational protein design platform. Xencor's platform applies high performance computing and advanced cell biology Cell biology
The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. to rapidly discover drugs with novel mechanisms and improved safety and efficacy. Xencor is a privately held biopharmaceutical company located in Monrovia, Calif.
For more information, visit http://www.xencor.com.
Chromos Molecular Systems Inc. is a public, Canadian biotechnology company leading the development of innovative therapies using a proprietary gene delivery and expression system for the production of therapeutic proteins and cell-mediated gene therapies. Chromos is achieving this objective with a unique mammalian chromosome technology platform from which multiple product candidates can be developed. Chromos' technology, referred to as the ACE System (artificial chromosome
For more information call 604/415-7100 or visit http://www.chromos.com.